Amycretin vs Cagrilintide
GLP-1 and amylin agonism combined in a single molecule, not a two-drug combination. A long-acting amylin analog built for once-weekly dosing and GLP-1 pairing. Side by side: type, evidence tier, receptor, molecular weight, and half-life — the same fields as each monograph, rearranged so the engineering difference is visible.
Amycretin | Cagrilintide | |
|---|---|---|
| Also known as | — | — |
| Type | Analog | Analog |
| Evidence | Investigational | Investigational |
| Family | Incretins & metabolic | Incretins & metabolic |
| Class | Unimolecular GLP-1 + amylin receptor agonist (peptide) | Long-acting amylin analog (acylated peptide) |
| Receptor | GLP-1 receptor + amylin receptors | Amylin receptors (calcitonin receptor + RAMP) |
| Molecular weight | ≈7,900 Da | ~4,408.9 Da |
| Half-life | ~days (weekly SC dosing) | |
| Based on | Amylin | Amylin |
Half-life bars are on a logarithmic scale across the molecules shown. Reference values for the native or representative form — educational only, not medical or dosing advice.
Common questions
- What is the difference between Amycretin and Cagrilintide?
- Amycretin is an engineered analog based on Amylin; Cagrilintide is an engineered analog based on Amylin. Amycretin signals at GLP-1 receptor + amylin receptors; Cagrilintide signals at Amylin receptors (calcitonin receptor + RAMP).
- How do the half-lives of Amycretin and Cagrilintide compare?
- The reported circulating half-life of Amycretin is ~days (weekly SC dosing); Cagrilintide is ~7 days (159-195 h). These are reference values for the native or representative form — educational only, not dosing advice.
Prefer the other order? Cagrilintide vs Amycretin. Or open the interactive comparison tool to add more molecules.